Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma Journal Article


Authors: Moskowitz, A. J.; Hamlin, P. A. Jr; Perales, M. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Graustein, T.; Zelenetz, A. D.; Moskowitz, C. H.
Article Title: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
Abstract: Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL. Patients with relapsed and refractory HL who were ineligible for autologous stem-cell transplantation (ASCT), or for whom this treatment failed, received bendamustine 120 mg/m(2) as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support. The primary end point was overall response rate (ORR). A secondary end point was referral rate to allogeneic stem-cell transplantation (alloSCT) for patients deemed eligible for alloSCT at the time of enrollment. Of the 36 patients enrolled, 34 were evaluable for response. Patients had received a median of four prior treatments, and 75% had relapsed after ASCT. The ORR by intent-to-treat analysis was 53%, including 12 complete responses (33%) and seven partial responses (19%). The response rate among evaluable patients was 56%. Responses were seen in patients with prior refractory disease, prior ASCT, and prior alloSCT; however, no responses were seen in patients who relapsed within 3 months of ASCT. The median response duration was 5 months. Five patients (20% of those eligible) proceeded to alloSCT after treatment with bendamustine. Grade ≥ 3 adverse events were infrequent and most commonly included thrombocytopenia (20%), anemia (14%), and infection (14%). This study confirms the efficacy of bendamustine in heavily pretreated patients with HL. These results support current and future studies evaluating bendamustine combinations in relapsed and refractory HL.
Keywords: adult; treatment outcome; aged; middle aged; antineoplastic agent; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; drug administration schedule; recurrence; alkylating agent; bendamustine; drug resistance; pathology; drug resistance, neoplasm; hodgkin disease; antineoplastic agents, alkylating; recurrent disease; drug administration; chlormethine derivative; nitrogen mustard compounds
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 4
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-02-01
Start Page: 456
End Page: 460
Language: English
DOI: 10.1200/jco.2012.45.3308
PUBMED: 23248254
PROVIDER: scopus
PMCID: PMC3862960
DOI/URL:
Notes: --- - "Export Date: 1 April 2013" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Carol Portlock
    178 Portlock
  2. Craig Moskowitz
    373 Moskowitz
  3. Ariela Noy
    205 Noy
  4. Maria Lia Palomba
    121 Palomba
  5. Steven M Horwitz
    351 Horwitz
  6. Andrew D Zelenetz
    551 Zelenetz
  7. Miguel-Angel Perales
    365 Perales
  8. Alison Moskowitz
    141 Moskowitz
  9. Paul Hamlin
    170 Hamlin
  10. Matthew J Matasar
    119 Matasar
  11. David J Straus
    205 Straus